Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NCCN Guidelines Insights: Breast Cancer, Version 1.2017.
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Gradishar WJ, et al. J Natl Compr Canc Netw. 2017 Apr;15(4):433-451. doi: 10.6004/jnccn.2017.0044. J Natl Compr Canc Netw. 2017. PMID: 28404755
Tamoxifen and contralateral breast cancer.
O'Regan R, Jordan VC, Gradishar WJ. O'Regan R, et al. J Am Coll Surg. 1999 Jun;188(6):678-83. doi: 10.1016/s1072-7515(99)00057-5. J Am Coll Surg. 1999. PMID: 10359362 Review. No abstract available.
Selective estrogen-receptor modulators in 2001.
O'Regan RM, Gradishar WJ. O'Regan RM, et al. Oncology (Williston Park). 2001 Sep;15(9):1177-85, 1189-90; discussion 1190-4. Oncology (Williston Park). 2001. PMID: 11589065 Free article.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Pagani O, et al. N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1. N Engl J Med. 2014. PMID: 24881463 Free PMC article. Clinical Trial.
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).
Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Shulman LN, et al. J Clin Oncol. 2014 Aug 1;32(22):2311-7. doi: 10.1200/JCO.2013.53.7142. Epub 2014 Jun 16. J Clin Oncol. 2014. PMID: 24934787 Free PMC article. Clinical Trial.
Optimizing Endocrine Therapy for Breast Cancer.
Zelnak AB, O'Regan RM. Zelnak AB, et al. J Natl Compr Canc Netw. 2015 Aug;13(8):e56-64. doi: 10.6004/jnccn.2015.0125. J Natl Compr Canc Netw. 2015. PMID: 26285250 Review.
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA. Gradishar WJ, et al. J Natl Compr Canc Netw. 2018 Mar;16(3):310-320. doi: 10.6004/jnccn.2018.0012. J Natl Compr Canc Netw. 2018. PMID: 29523670
163 results